The primary obstacle in treating advanced cancer and persistent infections is not always the lack of a potent drug, but the cell's ability to get rid of it. This phenomenon, known as Multidrug Resistance (MDR), often functions like a sump pump in a basement: as quickly as a clinician pours therapeutic "water" into the cell, the cell pumps it back out into the extracellular space.
Research across oncology, microbiology, and pharmacology is converging on a shared strategy: if we cannot stop the cell from wanting to eject the drug, we must disable the pumps themselves.
The Sump Pump Problem
At the heart of MDR are ATP-binding cassette (ABC) transporters, a family of transmembrane proteins that use energy to move molecules across cell membranes. The most notorious of these is P-glycoprotein (P-gp), also known as ABCB1. In a healthy body, these pumps protect vital organs by ejecting toxins. In a tumor, they are hijacked to eject chemotherapy agents like paclitaxel or doxorubicin before they can reach their targets.
As Wei Zhang and colleagues demonstrate in Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine, downregulating these transporters allows drugs to accumulate to lethal concentrations within cells that were previously "immune" to treatment.
Clogging the Machinery
One way to stop a pump is to physically jam it. This "functional inhibition" does not require changing how much of the protein the cell produces; instead, it uses a small molecule to clog the transporter's pore.
Xing-Duo Dong and Xiubin Ma have shown that the BTK inhibitor RN486 can effectively "clog" the ABCB1 pump. In their work, Bruton’s Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells, they found that RN486 restores drug potency without altering the total amount of protein expressed by the cell. This suggests that repurposing existing kinase inhibitors as "chemosensitizers" could be a rapid path to clinical application.
Silencing the Blueprint
A more permanent solution is to prevent the cell from building the pumps in the first place. This involves targeting the signaling pathways and transcription factors that tell the cell to overproduce ABC transporters.
- Signaling Cascades: Zheng Han and Meng Liu found that inhibiting the p38 MAPK pathway significantly lowers the expression of P-gp and MRP1, re-sensitizing colon cancer cells to treatment (Inhibition of p38 MAPK increases the sensitivity of 5‑fluorouracil‑resistant SW480 human colon cancer cells to noscapine).
- Transcriptional Control: Youxiang Hou identified the FOXM1–ABCC5 axis as a master regulator of drug efflux in nasopharyngeal carcinoma. By blocking FOXM1, they effectively cut off the "orders" to build more ABCC5 pumps (The FOXM1–ABCC5 axis contributes to paclitaxel resistance in nasopharyngeal carcinoma cells).
- Gene Editing: Modern tools like CRISPR/Cas9 are being explored to directly knock out the genes responsible for these transporters, as reviewed by Lu Huang in Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer.
The Nanotech Bypass
If the pumps are located on the cell membrane, one way to beat them is to enter the cell through a different door. Nanotechnology allows for "stealth" delivery systems that bypass surface-level efflux mechanisms.
Huilin Huang and Weihong Guo utilized melanin-based nanoparticles to deliver drugs via endocytosis—a process where the cell engulfs the entire particle—effectively shielding the drug from efflux pumps until it is safely inside (Natural Melanin-Based Nanoparticles With Combined Chemo/Photothermal/Photodynamic Effect Induce Immunogenic Cell Death (ICD) on Tumor).
Furthermore, "co-delivery" systems, such as the liposomes developed by Jie Meng and Xian‐Da Yang, package a cytotoxic drug (Paclitaxel) with a sensitizer (Resveratrol). This ensures that the "pump inhibitor" arrives at the exact same time and place as the "poison," maximizing the chance of success (Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo).
Natural Products as Adjuvants
A significant portion of this research focuses on natural compounds that have evolved to interact with biological membranes. Compounds from Traditional Chinese Medicine (TCM), such as tetrandrine, berberine, and bufadienolides (from toad venom), have shown a remarkable ability to inhibit P-gp.
As Xi Chen notes in Tailoring traditional Chinese medicine in cancer therapy, these natural metabolites can restore the intracellular concentration of drugs in refractory tumors. Similarly, Jie Zhang highlights how cantharidin induces a "double-hit" by causing DNA damage while simultaneously suppressing P-gp expression (Cantharidin: a double-edged sword in medicine and toxicology).
Beyond Cancer: Bacteria and Fungi
The "sump pump" mechanism is a universal biological defense. In Advances in Pharmacology and Toxicology of Marine, Haigang Wu discusses how the alkaloid matrine can downregulate the AcrAB-ToLC system in bacteria, restoring the sensitivity of multidrug-resistant strains to antibiotics.
In the agricultural and clinical fungal space, Will Jeong and colleagues propose using siRNA to silence ABC transporters in fungi, potentially extending the lifespan of existing fungicides (siRNA-Mediated Silencing of Antifungal Resistance Genes: A Research Protocol).
By viewing drug resistance as a mechanical problem of transport, researchers are moving toward a future where "untreatable" diseases are made vulnerable once again by simply turning off the pumps.